<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938664</url>
  </required_header>
  <id_info>
    <org_study_id>H-32241</org_study_id>
    <secondary_id>5P50DA018197-09</secondary_id>
    <nct_id>NCT01938664</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Candesartan as a Treatment for Cocaine Dependence</brief_title>
  <official_title>Pilot Study of Candesartan: An Angiotensin Receptor Blocker as a Treatment for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a drug called Candesartan will help to reduce use of
      cocaine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The noradrenergic system may play an important role in cocaine addiction in humans.
      Angiotensin II (Ang II) is known to enhance noradrenergic activity, which contributes to
      effects on blood pressure and sympathetic nervous system responses to stress. Inhibition of
      Ang II has been shown to reduce cravings for stimulants, including cocaine and
      methamphetamine.

      This clinical trial among 75 cocaine-dependent subjects is designed to test the efficacy of
      the Angiotensin II receptor antagonist, Candesartan, for treatment of cocaine dependence. The
      results of this study will provide medical safety and efficacy data, and will guide future
      pharmacotherapy trials using this class of medications for cocaine addiction.

      This 8-week trial includes a 1-week titration of the medication and 7-weeks of full dose
      medication (weeks 2-8), with all subjects receiving the active agent.

      At the conclusion of the trial, subjects who wish to be referred to an appropriate treatment
      program or treatment research program will be assisted with a referral.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results of interim efficacy analysis showed results were not promising.
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure># of Participants With Presence of Cocaine Metabolites Via Urinalysis</measure>
    <time_frame>thrice weekly, baseline thru week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure># of Participants Retained in Study</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of Participants With Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Candesartan will be well tolerated without significant side effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Candesartan w Cognitive Behavior Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo w Cognitive Behavior Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill to mimic Candesartan for study duration. CBT optional thru study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan with CBT</intervention_name>
    <description>8 mg, po (by mouth)</description>
    <arm_group_label>Candesartan w Cognitive Behavior Therapy</arm_group_label>
    <other_name>atacand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo with CBT</intervention_name>
    <arm_group_label>Placebo w Cognitive Behavior Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for study entry, all subjects must satisfy the following criteria:

          1. Age 18 to 64 years inclusive;

          2. Females either must be of non-child bearing potential (i.e., surgically sterilized or
             postmenopausal) or must be using adequate contraception, have a negative pregnancy
             test, and must agree to continue to use such precautions for the duration of the
             study.

          3. Meets Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV-TR)
             criteria for a principal diagnosis of cocaine dependence as confirmed by the MINI
             and/or as per PI/study investigator's examination of the patient during screening.
             (Per DSM-IV-TR, principal diagnosis is the condition that is the primary target of
             treatment at the time of presentation);

          4. Motivated to discontinue or reduce cocaine use during the period of the study, as
             evidenced both by the judgment of the Investigator or designee and by the subject's
             compliance level with the requirement for attendance at clinic visits such that the
             urine sample requirements for inclusion criteria #6 is fully met;

          5. Has a positive pattern of cocaine usage as determined by provision of at least one
             cocaine positive urine sample (benzoylecgonine (BE) level at least 300 ng/ml) during
             the screening period; typically conducted over a 7-14 day period.

          6. In good general health as determined by self-reported and/or computer-based medical
             history, general clinical examination, and laboratory tests;

          7. Has provided written informed consent.

          8. Are cooperative, willing and able to participate and adhere to the protocol
             requirements

        Exclusion Criteria:

        Subjects will be excluded from the study if one or more of the following statements are
        applicable:

          1. Subject is taking angiotensin-converting enzyme (ACE) inhibitors such as benazepril
             (Lotensin, in Lotrel), captopril (Capoten, in Capozide), enalapril (Vasotec, in
             Lexxel, in Vaseretic), fosinopril (Monopril), lisinopril (Prinivil, Zestril, in
             Prinzide, in Zestoretic), moexipril (Univasc, in Uniretic), perindopril, (Aceon),
             quinapril (Accupril, in Accuretic, in Quinaretic), ramipril (Altace), and trandolapril
             (Mavik, in Tarka); lithium (Eskalith Controlled-Release, Eskalith, Lithobid);

          2. Subject is on psychotropic medications, an MAOI, or an opiate antagonist;

          3. Subject is currently taking a dopaminergic, dopamine-blocking, dopamine-modulating, or
             other central dopamine-altering drug (e.g., antipsychotic drugs); a monoamine oxidase
             inhibitor (MAOI); or an opiate antagonist;

          4. Subject has an unstable medical, neurologic, or psychiatric illness that would
             interfere with the subject's safety, ability to participate in the study, or the
             interpretability of data. Subjects who meet the DSM-IV-R criteria for psychosis,
             schizophrenia, bipolar disorder or clinically significant suicidal ideation as
             assessed by the PI/study investigator and/or the MINI will be excluded. Subjects who
             have been taking stable doses of antidepressants for at least 3 months at the time the
             consent is signed will be allowed onto the study unless those antidepressants are of
             the types specified under exclusion criteria #3,above;

          5. Subject is dependent on benzodiazepines, barbiturates, amphetamines, opiates
             (including methadone or buprenorphine maintenance treatment) according to the DSM-IV-R
             and as assessed by the PI/study investigator and/or the MINI; 6

          6. Subject is, in the investigator's opinion, at risk of requiring medical detoxification
             for alcohol dependence during the study;

          7. Subject has participated in another clinical trial or received any other
             investigational compound within 7 days prior to being randomized into this study;

          8. Significant medical conditions (e.g., major cardiovascular, renal, endocrine, hepatic
             disorders, immunosuppressive disorders) such as abnormal liver function (with
             laboratory findings of serum glutamic oxaloacetic transaminase (SGOT) or serum
             glutamic-pyruvic transaminase (SGPT) greater than three times normal), hypotension,
             hypertension, a current cardiac condition, and those having a high risk of
             cardiovascular disease, seizure disorder, or another significant underlying medical
             condition which would contraindicate Candesartan treatment;

          9. Upon review of a compilation of screening data, at the discretion of the PI/study
             investigator, a participant may be excluded from the study if they test positive
             during the screening process for any substance other than cocaine or marijuana;

         10. Female subjects with a positive pregnancy test, lactating mothers, women refusing to
             agree to pregnancy tests during the study, women who are planning to become pregnant
             during the period of the trial or women of child-bearing potential who refuse to agree
             to use adequate contraception during the study. Acceptable contraceptive methods are
             oral or parenteral hormonal contraceptives, intrauterine device (IUD), or barrier and
             spermicide, but not abstinence; OR Male subjects refusing to agree to use adequate
             contraception during the study, or males who are part of a couple planning to become
             pregnant during the period of the trial;

         11. Any other factor that per the Investigator/designee would make the subject unsafe or
             unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <results_first_submitted>August 8, 2019</results_first_submitted>
  <results_first_submitted_qc>August 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2019</results_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Thomas R. Kosten, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>dependence</keyword>
  <keyword>pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Candesartan w Cognitive Behavior Therapy</title>
          <description>Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
Candesartan with CBT: 8 mg, po (by mouth)</description>
        </group>
        <group group_id="P2">
          <title>Placebo w Cognitive Behavior Therapy</title>
          <description>Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
Placebo with CBT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Candesartan w Cognitive Behavior Therapy</title>
          <description>Titration up to 8mg wk 1-4. Continue on 8mg thru wk 8. CBT optional thru study.
Candesartan with CBT: 8 mg, po (by mouth)</description>
        </group>
        <group group_id="B2">
          <title>Placebo w Cognitive Behavior Therapy</title>
          <description>Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
Placebo with CBT</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title># of Participants With Presence of Cocaine Metabolites Via Urinalysis</title>
        <time_frame>thrice weekly, baseline thru week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan w Cognitive Behavior Therapy</title>
            <description>Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
Candesartan with CBT: 8 mg, po (by mouth)</description>
          </group>
          <group group_id="O2">
            <title>Placebo w Cognitive Behavior Therapy</title>
            <description>Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
Placebo with CBT</description>
          </group>
        </group_list>
        <measure>
          <title># of Participants With Presence of Cocaine Metabolites Via Urinalysis</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title># of Participants Retained in Study</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan w Cognitive Behavior Therapy</title>
            <description>Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
Candesartan with CBT: 8 mg, po (by mouth)</description>
          </group>
          <group group_id="O2">
            <title>Placebo w Cognitive Behavior Therapy</title>
            <description>Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
Placebo with CBT</description>
          </group>
        </group_list>
        <measure>
          <title># of Participants Retained in Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title># of Participants With Adverse Events</title>
        <description>Candesartan will be well tolerated without significant side effects.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan w Cognitive Behavior Therapy</title>
            <description>Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
Candesartan with CBT: 8 mg, po (by mouth)</description>
          </group>
          <group group_id="O2">
            <title>Placebo w Cognitive Behavior Therapy</title>
            <description>Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
Placebo with CBT</description>
          </group>
        </group_list>
        <measure>
          <title># of Participants With Adverse Events</title>
          <description>Candesartan will be well tolerated without significant side effects.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Candesartan w Cognitive Behavior Therapy</title>
          <description>Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
Candesartan with CBT: 8 mg, po (by mouth)</description>
        </group>
        <group group_id="E2">
          <title>Placebo w Cognitive Behavior Therapy</title>
          <description>Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
Placebo with CBT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Kosten, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-794-7032</phone>
      <email>kosten@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

